Grünenthal's resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. Grünenthal is running...

Related Keywords

Germany ,United States ,Grunenthal ,Nordrhein Westfalen ,Japan ,Switzerland ,South Africa ,Swiss ,Japanese ,America ,Christopher Jansen ,Jan Adams ,Florian Dieckmann ,Instagram ,Grunenthal Group ,European Union ,National Institute Of Arthritis ,Drug Administration Breakthrough Therapy Designation ,Route Of Administration Parenteral ,Linkedin ,Drug Administration ,Breakthrough Therapy Designation ,Chief Scientific Officer ,Transient Receptor Potential Vanilloid ,Latin America ,Marketing Authorization Application ,Novaquest Capital Management ,Publication Prevalence Trends ,Site Specific Osteoarthritis From ,Findings From ,Global Burden ,Disease Study ,Andmarkets Report ,Osteoarthritis Therapeutics Market ,Drug Type ,Distribution Channel ,Hospital Pharmacies ,Purchasing Pattern ,Prescription Drugs ,Skin Diseases ,What Causes Osteoarthritis ,Grünenthal Group ,